Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers.

Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, Kolli D, Noffsinger L, Brown R, McGuire M, Fu S, Piha-Paul S, Naing A, Conley AP, Benjamin RS, Kaur I, Bosch ML.

Clin Cancer Res. 2018 Aug 15;24(16):3845-3856. doi: 10.1158/1078-0432.CCR-17-2707. Epub 2018 Jul 17.

PMID:
30018119
2.

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 Jun 29;16(1):179. doi: 10.1186/s12967-018-1552-1.

3.

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6. Erratum in: J Transl Med. 2018 Jun 29;16(1):179.

4.

Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities.

Garrett M, Sperry J, Braas D, Yan W, Le TM, Mottahedeh J, Ludwig K, Eskin A, Qin Y, Levy R, Breunig JJ, Pajonk F, Graeber TG, Radu CG, Christofk H, Prins RM, Lai A, Liau LM, Coppola G, Kornblum HI.

Cancer Metab. 2018 Apr 17;6:4. doi: 10.1186/s40170-018-0177-4. eCollection 2018.

5.

Precision Medicine in Pediatric Neurooncology: A Review.

Mochizuki AY, Frost IM, Mastrodimos MB, Plant AS, Wang AC, Moore TB, Prins RM, Weiss PS, Jonas SJ.

ACS Chem Neurosci. 2018 Jan 17;9(1):11-28. doi: 10.1021/acschemneuro.7b00388. Epub 2017 Dec 27. Review.

PMID:
29199818
6.

Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas.

Chung LK, Pelargos PE, Chan AM, Demos JV, Lagman C, Sheppard JP, Nguyen T, Chang YL, Hojat SA, Prins RM, Liau LM, Nghiemphu L, Lai A, Cloughesy TF, Yong WH, Gordon LK, Wadehra M, Yang I.

Brain Tumor Pathol. 2018 Jan;35(1):1-9. doi: 10.1007/s10014-017-0300-1. Epub 2017 Sep 8.

7.

Detection of immune responses after immunotherapy in glioblastoma using PET and MRI.

Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM.

Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10220-10225. doi: 10.1073/pnas.1706689114. Epub 2017 Sep 5.

8.

Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme.

Qin Y, Takahashi M, Sheets K, Soto H, Tsui J, Pelargos P, Antonios JP, Kasahara N, Yang I, Prins RM, Braun J, Gordon LK, Wadehra M.

J Neurooncol. 2017 Aug;134(1):29-40. doi: 10.1007/s11060-017-2507-8. Epub 2017 Jun 9.

9.

Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.

Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM.

Neuro Oncol. 2017 Jun 1;19(6):796-807. doi: 10.1093/neuonc/now287.

10.

PD-1 blockade enhances the vaccination-induced immune response in glioma.

Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM.

JCI Insight. 2016 Jul 7;1(10). pii: e87059.

11.

TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination.

Hsu M, Sedighim S, Wang T, Antonios JP, Everson RG, Tucker AM, Du L, Emerson R, Yusko E, Sanders C, Robins HS, Yong WH, Davidson TB, Li G, Liau LM, Prins RM.

Cancer Immunol Res. 2016 May;4(5):412-418. doi: 10.1158/2326-6066.CIR-15-0240. Epub 2016 Mar 11.

12.

Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.

Everson RG, Antonios JP, Lisiero DN, Soto H, Scharnweber R, Garrett MC, Yong WH, Li N, Li G, Kruse CA, Liau LM, Prins RM.

Neuro Oncol. 2016 Mar;18(3):368-78. doi: 10.1093/neuonc/nov153. Epub 2015 Sep 1.

13.

2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.

Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, Pai MY, Li S, Ta L, Fazlollahi F, Chen C, Prins RM, Teitell MA, Nathanson DA, Lai A, Faull KF, Jiang M, Clarke SG, Cloughesy TF, Graeber TG, Braas D, Christofk HR, Jung ME, Reue K, Huang J.

Cell Metab. 2015 Sep 1;22(3):508-15. doi: 10.1016/j.cmet.2015.06.009. Epub 2015 Jul 16.

14.

pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI.

Harris RJ, Cloughesy TF, Liau LM, Prins RM, Antonios JP, Li D, Yong WH, Pope WB, Lai A, Nghiemphu PL, Ellingson BM.

Neuro Oncol. 2015 Nov;17(11):1514-24. doi: 10.1093/neuonc/nov106. Epub 2015 Jun 24.

15.

Radial mobility and cytotoxic function of retroviral replicating vector transduced, non-adherent alloresponsive T lymphocytes.

Erickson KL, Hickey MJ, Kato Y, Malone CC, Owens GC, Prins RM, Liau LM, Kasahara N, Kruse CA.

J Vis Exp. 2015 Feb 11;(96). doi: 10.3791/52416.

16.

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.

Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, Pennell CA, Olin MR.

J Immunother Cancer. 2014 Dec 16;2(1):46. doi: 10.1186/s40425-014-0046-9. eCollection 2014.

17.

Dominant B-cell epitopes from cancer/stem cell antigen SOX2 recognized by serum samples from cancer patients.

Shih J, Rahman M, Luong QT, Lomeli SH, Riss J, Prins RM, Gure AO, Zeng G.

Am J Clin Exp Immunol. 2014 Aug 15;3(2):84-90. eCollection 2014.

18.

The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells.

Lisiero DN, Soto H, Everson RG, Liau LM, Prins RM.

J Immunother Cancer. 2014 Apr 15;2:8. doi: 10.1186/2051-1426-2-8. eCollection 2014.

19.

Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients.

Everson RG, Jin RM, Wang X, Safaee M, Scharnweber R, Lisiero DN, Soto H, Liau LM, Prins RM.

J Immunother Cancer. 2014 May 13;2:10. doi: 10.1186/2051-1426-2-10. eCollection 2014.

20.

Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas.

Lasky JL 3rd, Panosyan EH, Plant A, Davidson T, Yong WH, Prins RM, Liau LM, Moore TB.

Anticancer Res. 2013 May;33(5):2047-56.

Supplemental Content

Loading ...
Support Center